+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Cancer Biological Therapy Market by Therapy Type (Cancer Vaccines, CAR T-Cell Therapy, Cytokine Therapy), Application (Breast Cancer, Colorectal Cancer, Hematologic Malignancies), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Cancer Biological Therapy Market by Therapy Type (Cancer Vaccines, CAR T-Cell Therapy, Cytokine Therapy), Application (Breast Cancer, Colorectal Cancer, Hematologic Malignancies), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030- Product Image
Sale

Cancer Biological Therapy Market by Therapy Type (Cancer Vaccines, CAR T-Cell Therapy, Cytokine Therapy), Application (Breast Cancer, Colorectal Cancer, Hematologic Malignancies), Administration Route, End User, Distribution Channel - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 188 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6011650
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Biological therapy is reshaping cancer treatment by leveraging targeted scientific innovations and personalized approaches. Senior decision-makers can anticipate meaningful shifts in care pathways as collaboration and new platform technologies deepen the sector’s impact on patient outcomes and operational efficiency.

Market Snapshot: Cancer Biological Therapy Market Overview

The Cancer Biological Therapy Market grew from USD 72.42 billion in 2024 to USD 81.25 billion in 2025. It is expected to continue growing at a CAGR of 11.63%, reaching USD 140.21 billion by 2030. Market expansion is being driven by technological breakthroughs in recombinant DNA, monoclonal antibodies, and viral vector design within oncology, forming the backbone of new treatment modalities and fostering robust pipelines. Increased collaboration between academia, biotech, and pharma is accelerating therapy development and expanding clinical adoption, with policy shifts and supply chain innovation helping unlock greater global access.

Scope & Segmentation of the Cancer Biological Therapy Market

This report provides comprehensive coverage of key market segments, technological platforms, applications, distribution models, and regional variations—helping senior leaders inform both strategic planning and operational execution:

  • Therapy Types: Cancer vaccines, CAR T-cell therapies, cytokine therapies, gene therapies, monoclonal antibodies (including chimeric, humanized, fully human, and murine formats), oncolytic viral therapies.
  • Application Areas: Breast cancer, colorectal cancer, hematologic malignancies, melanoma, non-small cell lung cancer, prostate cancer.
  • Administration Routes: Intramuscular, intravenous, oral, subcutaneous.
  • End Users: Ambulatory care centers, home healthcare, hospitals, research laboratories, specialty clinics.
  • Distribution Channels: Direct sales, hospital pharmacies, online pharmacies, retail pharmacies.
  • Geographic Coverage: Americas (United States, Canada, Mexico, Brazil, Argentina), Europe, Middle East & Africa (including United Kingdom, Germany, France, Saudi Arabia, South Africa, among others), Asia-Pacific (covering China, India, Japan, Australia, South Korea, and more).
  • Leading Companies: F. Hoffmann-La Roche Ltd, Merck & Co., Bristol-Myers Squibb, Novartis International AG, Amgen, Pfizer, Johnson & Johnson, AstraZeneca, Gilead Sciences, and AbbVie.

Cancer Biological Therapy Market: Key Takeaways

  • Biological therapies are enabling more precise, patient-specific approaches that distinguish them from traditional cytotoxic treatments and offer the potential for improved long-term survival.
  • Strategic industry collaboration is essential for translating scientific discovery into scalable, clinically adopted solutions, with emerging technology platforms driving pipeline diversification.
  • Operational challenges such as manufacturing scale-up, cold chain logistics, and evolving reimbursement models require coordinated stakeholder alignment to ensure broad patient access to cutting-edge therapies.
  • Adoption rates and therapy success depend on infrastructure maturity, regional policy incentives, and the capacity to tailor commercialization strategies to the local healthcare environment.
  • Innovation in data analytics, regulatory frameworks, and platform-based manufacturing is expanding both the potential and performance of biological therapies, keeping industry leaders focused on integrated, evidence-driven decision making.

Tariff Impact on Cancer Biological Therapy Access and Cost

Recent United States tariff adjustments introduced in 2025 are adding cost and complexity to the supply chain for cancer biological therapies. Increased import duties affect both raw materials and finished products, compelling manufacturers to reassess sourcing, renegotiate agreements, and explore local production. These tariffs are also influencing cost structures for hospitals and providers, making value-based contracting models and inter-industry advocacy more important to sustain patient access and continued market growth.

Research Methodology & Data Sources

Findings are grounded in a multi-source approach, leveraging secondary research, primary interviews, and advanced data triangulation. This includes reviews of scientific literature, regulatory filings, and direct input from industry leaders, ensuring data veracity and actionable insight.

Why This Report Matters for Senior Decision-Makers

  • Facilitates decisions on R&D investment, global market entry, and technology adoption based on reliable segmentation and trends analysis.
  • Empowers operational planning by outlining the practical impact of tariff changes, regulatory pathways, and evolving distribution models.
  • Highlights competitive dynamics, emerging platforms, and strategic partnership opportunities that are shaping the sector’s direction.

Conclusion

The cancer biological therapy market is defined by therapeutic innovation, regional shifts, and evolving operational strategies. Leaders who integrate clinical, operational, and commercial acumen will be positioned to deliver personalized care and maintain market leadership as the sector advances.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Emergence of personalized neoantigen vaccines leveraging patient-specific tumor profiles for improved immune response
5.2. Rapid clinical adoption of gene-edited CAR-T therapies with optimized safety switches to minimize cytokine release syndrome
5.3. Expansion of oncolytic virus platforms combined with immune checkpoint inhibitors for synergistic tumor eradication
5.4. Advancements in multispecific antibody formats targeting immune checkpoint and costimulatory pathways for enhanced efficacy
5.5. Integration of AI-driven biomarker discovery to predict patient response to cancer biologics and accelerate development timelines
5.6. Growing interest in microbial-derived immunomodulators to reshape the tumor microenvironment and boost therapy response rates
5.7. Emerging off-the-shelf allogeneic NK cell therapies engineered for persistent activity and reduced graft-versus-host risks
5.8. Development of bispecific T-cell engagers with controlled half-life extensions for improved safety and dosing flexibility
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Cancer Biological Therapy Market, by Therapy Type
8.1. Introduction
8.2. Cancer Vaccines
8.3. CAR T-Cell Therapy
8.4. Cytokine Therapy
8.5. Gene Therapy
8.6. Monoclonal Antibodies
8.6.1. Chimeric
8.6.2. Human
8.6.3. Humanized
8.6.4. Murine
8.7. Oncolytic Viral Therapy
9. Cancer Biological Therapy Market, by Application
9.1. Introduction
9.2. Breast Cancer
9.3. Colorectal Cancer
9.4. Hematologic Malignancies
9.5. Melanoma
9.6. Non-Small Cell Lung Cancer
9.7. Prostate Cancer
10. Cancer Biological Therapy Market, by Administration Route
10.1. Introduction
10.2. Intramuscular
10.3. Intravenous
10.4. Oral
10.5. Subcutaneous
11. Cancer Biological Therapy Market, by End User
11.1. Introduction
11.2. Ambulatory Care Centers
11.3. Home Healthcare
11.4. Hospitals
11.5. Research Laboratories
11.6. Specialty Clinics
12. Cancer Biological Therapy Market, by Distribution Channel
12.1. Introduction
12.2. Direct Sales
12.3. Hospital Pharmacies
12.4. Online Pharmacies
12.5. Retail Pharmacies
13. Americas Cancer Biological Therapy Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Cancer Biological Therapy Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Cancer Biological Therapy Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. F. Hoffmann-La Roche Ltd
16.3.2. Merck & Co. Inc
16.3.3. Bristol-Myers Squibb Company
16.3.4. Novartis International AG
16.3.5. Amgen Inc
16.3.6. Pfizer Inc
16.3.7. Johnson & Johnson
16.3.8. AstraZeneca plc
16.3.9. Gilead Sciences, Inc
16.3.10. AbbVie Inc
17. ResearchAI
18. ResearchStatistics
19. ResearchContacts
20. ResearchArticles
21. Appendix
List of Figures
FIGURE 1. CANCER BIOLOGICAL THERAPY MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2030 (%)
FIGURE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CANCER BIOLOGICAL THERAPY MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. CANCER BIOLOGICAL THERAPY MARKET: RESEARCHAI
FIGURE 26. CANCER BIOLOGICAL THERAPY MARKET: RESEARCHSTATISTICS
FIGURE 27. CANCER BIOLOGICAL THERAPY MARKET: RESEARCHCONTACTS
FIGURE 28. CANCER BIOLOGICAL THERAPY MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER VACCINES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CAR T-CELL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CYTOKINE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CHIMERIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMAN, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HUMANIZED, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MURINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONCOLYTIC VIRAL THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HEMATOLOGIC MALIGNANCIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MELANOMA, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY NON-SMALL CELL LUNG CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ORAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
TABLE 56. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2030 (USD MILLION)
TABLE 57. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 58. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 59. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
TABLE 60. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
TABLE 61. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2024 (USD MILLION)
TABLE 62. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2025-2030 (USD MILLION)
TABLE 63. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
TABLE 64. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2030 (USD MILLION)
TABLE 65. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 66. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 67. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 68. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 69. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 70. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 71. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
TABLE 72. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
TABLE 73. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 74. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 75. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 76. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 77. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 78. GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 79. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 80. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 81. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 82. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 83. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 86. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 87. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 88. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 89. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 90. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 91. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 92. AMERICAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 93. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 94. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 95. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 96. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 97. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 98. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 99. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 100. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 101. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 102. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 103. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 106. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 107. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 108. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 109. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 110. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 111. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 112. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 113. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 114. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 115. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 118. CANADA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 119. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 120. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 121. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 122. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 123. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 124. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 125. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 126. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 127. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 130. MEXICO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 131. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 132. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 133. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 134. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 135. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 136. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 137. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 138. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 139. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 142. BRAZIL CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 143. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 144. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 145. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 146. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 147. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 148. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 149. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 150. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 151. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 152. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 153. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 154. ARGENTINA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 159. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 160. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 168. EUROPE, MIDDLE EAST & AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 173. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 174. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 175. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 176. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 177. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 180. UNITED KINGDOM CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 181. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 182. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 183. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 184. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 185. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 188. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 189. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 190. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 191. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 192. GERMANY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 193. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 196. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 197. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 198. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 199. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 200. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 201. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 202. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 203. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 204. FRANCE CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 215. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. RUSSIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 218. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 219. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 220. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 221. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 222. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 223. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 224. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 225. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 228. ITALY CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 229. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 230. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 231. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 232. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 233. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 234. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 235. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 240. SPAIN CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 241. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 242. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 253. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 254. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 255. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 256. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 265. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 266. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 267. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 268. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 269. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 278. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 279. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 280. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 281. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 282. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 283. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 284. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 285. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 286. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 287. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 288. DENMARK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 289. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 290. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 291. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 292. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 293. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 294. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 295. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 296. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 297. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 300. NETHERLANDS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 301. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
TABLE 302. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY THERAPY TYPE, 2025-2030 (USD MILLION)
TABLE 303. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 304. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 305. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 306. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 307. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2018-2024 (USD MILLION)
TABLE 308. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY ADMINISTRATION ROUTE, 2025-2030 (USD MILLION)
TABLE 309. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. QATAR CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 312. QATAR CANCER BIOLOGICAL THERAPY

Samples

Loading
LOADING...

Companies Mentioned

  • F. Hoffmann-La Roche Ltd
  • Merck & Co. Inc
  • Bristol-Myers Squibb Company
  • Novartis International AG
  • Amgen Inc
  • Pfizer Inc
  • Johnson & Johnson
  • AstraZeneca plc
  • Gilead Sciences, Inc
  • AbbVie Inc

Table Information

Report AttributeDetails
No. of Pages188
PublishedAugust 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 81.25 Billion
Forecasted Market Value ( USD ) by 2030 $ 140.21 Billion
Compound Annual Growth Rate11.6%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis Report 2025 - Product Image

Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis Report 2025

  • Report
  • 200 Pages
  • Global
From
Immuno-Oncology Service Market by Therapy Type (Cancer Vaccines, Car-T Therapy, Checkpoint Inhibitors), Cancer Indication (Breast Cancer, Leukemia, Lung Cancer), End User, Distribution Channel - Global Forecast 2025-2030 - Product Image

Immuno-Oncology Service Market by Therapy Type (Cancer Vaccines, Car-T Therapy, Checkpoint Inhibitors), Cancer Indication (Breast Cancer, Leukemia, Lung Cancer), End User, Distribution Channel - Global Forecast 2025-2030

  • Report
  • 199 Pages
  • Global
From
CD Antigen Cancer Therapy Market by Therapy Type (Antibody-Drug Conjugates, Chimeric Antigen Receptor (CAR) T-cell Therapy, Monoclonal Antibodies), Cancer Type (Hematological Malignancies, Solid Tumors) - Global Forecast 2025-2030 - Product Image

CD Antigen Cancer Therapy Market by Therapy Type (Antibody-Drug Conjugates, Chimeric Antigen Receptor (CAR) T-cell Therapy, Monoclonal Antibodies), Cancer Type (Hematological Malignancies, Solid Tumors) - Global Forecast 2025-2030

  • Report
  • 198 Pages
  • Global
From
T-Cell Malignancies - Pipeline Insight, 2025 - Product Image

T-Cell Malignancies - Pipeline Insight, 2025

  • Drug Pipelines
  • 280 Pages
  • Global
From
T-Cell Therapy Market by Type of Therapy, Target Indication, Target Antigen, Company Size, Geographical Regions, Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035 - Product Image

T-Cell Therapy Market by Type of Therapy, Target Indication, Target Antigen, Company Size, Geographical Regions, Leading Players and Sales Forecast of Therapies, Industry Trends and Global Forecasts to 2035

  • Report
  • 1048 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.